Greenridge Global Has Lowered Expectations for EUDA Health (NASDAQ:EUDA) Stock Price

EUDA Health (NASDAQ:EUDA) had its price target decreased by equities research analysts at Greenridge Global from $6.00 to $2.75 in a report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Greenridge Global’s price target indicates a potential upside of 391.07% from the company’s previous close.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of EUDA Health in a research report on Friday, January 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $2.75.

EUDA Health Stock Performance

NASDAQ:EUDA traded down $0.17 on Monday, reaching $0.56. The company’s stock had a trading volume of 113,214 shares, compared to its average volume of 407,699. The firm has a market cap of $21.17 million, a PE ratio of -4.72 and a beta of -0.11. The business’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $2.04. EUDA Health has a 1-year low of $0.60 and a 1-year high of $4.30.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in EUDA Health stock. Jane Street Group LLC bought a new position in EUDA Health Holdings Limited (NASDAQ:EUDA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,675 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 0.07% of EUDA Health as of its most recent filing with the Securities and Exchange Commission (SEC). 4.35% of the stock is currently owned by institutional investors and hedge funds.

EUDA Health Company Profile

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.